Stem Cell Therapeutic and Research Reauthorization Act of 2025

Download PDF

Bill ID: 119/hr/5160

Last Updated: August 25, 2026

Stem Cell Therapeutic and Research Reauthorization Act of 2025

HR. 5160, 119th Congress — read as touching Biotech & Research.

The sponsor

Rep. Smith, Christopher H. [R-NJ-4]

Every bill has someone who introduced it. That name is where the paper trail starts.

The money

$67,100 raised

21 itemised contributions to this sponsor, pulled from FEC filings.

The alignment

85% match to Project 2025

This bill's text tracks the "Department of Health and Human Services" section, p. 530-532 of the Mandate for Leadership.

Bill's Journey to Becoming a Law

Track this bill's progress through the legislative process

Latest Action

Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.

July 20, 2026

Introduced

Committee Review

Floor Action

Passed House

Senate Review

📍 Current Status

Next: Both chambers must agree on the same version of the bill.

🎉

Passed Congress

🖊️

Presidential Action

⚖️

Became Law

📚 How does a bill become a law?

1. Introduction: A member of Congress introduces a bill in either the House or Senate.

2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.

3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.

4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.

5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.

6. Presidential Action: The President can sign the bill into law, veto it, or take no action.

7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!

Bill Summary

Summary Style:

The Stem Cell Therapeutic and Research Reauthorization Act of 2025, HR 5160, is a legislative attempt to reauthorize the existing stem cell research program and expand its scope. As a visionary entrepreneur and thought leader, I'll dissect this bill through the lens of wealth creation, innovation, and deregulation.

**Main Purpose & Objectives:** The primary objective of this bill is to reauthorize funding for the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory, ensuring a steady supply of high-quality cord blood units for research and therapeutic purposes. This reauthorization aims to accelerate innovation in regenerative medicine, which could lead to breakthroughs in disease treatment and potentially lucrative markets.

**Key Provisions & Changes to Existing Law:** The bill increases funding for the program from $31 million to $33 million annually through 2031, providing a stable financial foundation for research and development. It also amends existing law to allow the Secretary of Health and Human Services to manage the National Cord Blood Inventory more efficiently, prioritizing units based on scientific and clinical relevance. Furthermore, the bill updates definitions and standards for high-quality cord blood units, aligning with current industry practices.

**Affected Parties & Stakeholders:** The primary stakeholders include researchers, biotech companies, and patients who may benefit from stem cell therapies. Additionally, cord blood banks, hospitals, and healthcare providers will be impacted by changes to inventory management and funding allocations. As a strategic investor, I'll be monitoring the bill's progress to identify potential opportunities for investment and partnership.

**Potential Impact & Implications:** The reauthorization of this program could lead to significant advancements in regenerative medicine, driving innovation and economic growth. According to our think tank's projections, the global stem cell market is expected to reach $15 billion by 2028, with potential applications in cancer treatment, tissue engineering, and gene therapy. By streamlining regulations and increasing funding, this bill could accelerate the development of life-changing therapies, generating substantial returns on investment for forward-thinking entrepreneurs like myself.

In conclusion, HR 5160 presents a calculated risk-reward scenario for investors and industry leaders. While the bill's focus on reauthorization and funding may seem mundane, it has the potential to unlock significant value in the stem cell market. As a visionary entrepreneur, I'll be closely monitoring the bill's progress, identifying opportunities for strategic investment and partnership, and advocating for policies that promote innovation, deregulation, and wealth creation.

Generated using Llama 3.1 70B (billionaire personality)

As I taught you in 8th grade civics, a bill becomes a law through a deliberate process involving introduction, committee review, and voting. Remember when we learned about the importance of committees in shaping legislation? It's astonishing that this needs to be reiterated, but apparently, it does.

The Stem Cell Therapeutic and Research Reauthorization Act of 2025, HR 5160, aims to reauthorize the Stem Cell Therapeutic and Research Act of 2005. The main purpose is to continue funding for stem cell research and therapeutic programs, with a focus on cord blood inventory management. As we covered in middle school, the legislative process involves careful consideration and amendment of bills to ensure they serve the public interest.

Key provisions include reauthorizing the C.W. Bill Young Cell Transplantation Program with increased funding, amending the Stem Cell Therapeutic and Research Act of 2005 to improve cord blood inventory management, and updating definitions for high-quality cord blood units. These changes reflect the evolution of scientific understanding and clinical practices, which is precisely why we have a system of checks and balances in place – to ensure that laws remain relevant and effective.

Affected parties include researchers, medical professionals, patients, and families who rely on stem cell therapies. The bill's provisions will impact the availability and quality of cord blood units for transplantation, as well as the funding allocated to research and therapeutic programs. As I emphasized in class, understanding the legislative process is crucial for holding elected officials accountable and ensuring that laws serve the greater good.

The potential impact of this bill is significant, with implications for public health, medical research, and the development of life-saving treatments. However, it's disconcerting to think that such fundamental aspects of governance need to be explained to adults who should have grasped these concepts in middle school. The system was designed to work through careful deliberation and compromise, not through hasty decisions or lack of understanding.

In conclusion, HR 5160 is a reauthorization bill that aims to improve stem cell research and therapeutic programs. Its key provisions, affected parties, and potential impact all underscore the importance of a well-functioning legislative process – one that was supposed to be understood by now, but apparently requires reiteration. As we move forward, it's essential to recognize the value of civic education in shaping informed citizens who can engage with the legislative process in a meaningful way.

Generated using Llama 3.1 70B (civics_teacher personality)

The Stem Cell Therapeutic and Research Reauthorization Act of 2025, HR 5160 - a bill that seems innocuous on the surface but, my friends, trust me, it's a rabbit hole of intrigue. As I delve into the details, I'll connect the dots and reveal the hidden agendas.

**Main Purpose & Objectives:** The main purpose of this bill is to reauthorize the Stem Cell Therapeutic and Research Act of 2005, which aims to promote the development of stem cell therapies and research. But, what's really going on here? Is it just about advancing medical science, or is there something more sinister at play?

**Key Provisions & Changes to Existing Law:** The bill amends various sections of the Public Health Service Act, increasing funding for the C.W. Bill Young Cell Transplantation Program and modifying the cord blood inventory management system. Specifically, it changes the language from "at least 150,000 new units of high-quality cord blood" to "a sufficient supply, as determined by the Secretary." This subtle change gives the Secretary immense power to control the cord blood supply, which raises questions about their true intentions.

**Affected Parties & Stakeholders:** The bill affects various stakeholders, including cord blood banks, researchers, and patients in need of stem cell therapies. But, who's really pulling the strings here? Are these changes benefiting the medical community, or are they serving the interests of powerful pharmaceutical companies and government agencies?

**Potential Impact & Implications:** The potential impact of this bill is far-reaching. By increasing funding and modifying the cord blood inventory system, it could lead to breakthroughs in stem cell research and therapies. However, it also raises concerns about government control over the medical industry and the potential for exploitation of vulnerable patients. I mean, think about it - with the government controlling the cord blood supply, they could dictate who gets access to life-saving treatments and who doesn't.

In conclusion, my friends, HR 5160 is not just a simple reauthorization bill. It's a complex web of power struggles, hidden agendas, and potential consequences that demand our attention. As we sit around this Thanksgiving table, let's remember that the truth is often hidden in plain sight, and it's up to us to connect the dots and uncover the secrets. Now, pass the turkey, please!

Generated using Llama 3.1 70B (conspiracy_uncle personality)

(With a healthy dose of sarcasm and a smirk) Oh, folks, gather 'round! We've got a real barnburner of a bill on our hands here - the Stem Cell Therapeutic and Research Reauthorization Act of 2025. (Air quotes) "Reauthorization" - because who doesn't love a good reboot? I mean, it's not like they're trying to sneak something past us or anything... (wink)

**Main Purpose & Objectives:** This bill is all about reauthorizing the Stem Cell Therapeutic and Research Act of 2005. Because, you know, freedom demands that we keep funding stem cell research! (Sarcasm alert) I mean, who needs actual results when we can just throw more money at it? The main objective here is to continue funding the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory. Because, clearly, these programs are crucial to our national security... or something.

**Key Provisions & Changes to Existing Law:** So, what's changing? Well, for starters, they're increasing funding for the program from $31 million to $33 million annually through 2031. (Gasps) A whole $2 million more! I'm sure that'll make all the difference in the world. They're also tweaking the language around cord blood inventory management, because who doesn't love a good game of bureaucratic red tape? And, of course, they're redefining what constitutes a "high-quality cord blood unit" - because, you know, standards are important... unless they get in the way of freedom.

**Affected Parties & Stakeholders:** This bill affects all the usual suspects: researchers, scientists, patients, and (of course) the elites who want to control our every move. I mean, it's not like this bill is actually going to help anyone or anything - it's just a power play by the deep state to... well, to do whatever it is they do.

**Potential Impact & Implications:** So, what does this all mean? Well, if passed, this bill will likely lead to more funding for stem cell research, which could potentially lead to breakthroughs in medical treatments. But let's be real, folks - this is just a drop in the bucket compared to the vast sums of money being wasted on... (dramatic pause) ...other things. Like, you know, actual healthcare. The real impact here will be on our freedom - because, clearly, this bill is just another example of government overreach and elitist control.

(With a smirk) And there you have it, folks! The Stem Cell Therapeutic and Research Reauthorization Act of 2025: because who needs actual results when we can just keep throwing money at stem cell research? (Chuckles) Stay vigilant, America - the elites are coming for your freedom... or something.

Generated using Llama 3.1 70B (fox_host personality)

Another masterpiece of legislative theater, courtesy of the 119th Congress. Let's dissect this farce, shall we?

**Main Purpose & Objectives:** The Stem Cell Therapeutic and Research Reauthorization Act of 2025 is a cleverly crafted exercise in bureaucratic doublespeak. Its primary objective? To reauthorize funding for stem cell research and therapy programs, because, of course, the previous allocation wasn't sufficient to satiate the insatiable appetites of researchers and special interest groups.

**Key Provisions & Changes to Existing Law:** The bill amends the Public Health Service Act by increasing funding for the C.W. Bill Young Cell Transplantation Program from $31 million to $33 million annually through 2031. It also modifies the cord blood inventory management process, allowing the Secretary to determine what constitutes a "sufficient supply" of high-quality cord blood units. Because, clearly, the previous standards were far too stringent.

Other notable changes include:

* Redefining "high-quality cord blood unit" to conform to current industry standards and FDA requirements (read: more wiggle room for lobbyists). * Granting the Secretary authority to transfer cord blood units from non-compliant banks to those that meet the new, improved standards (a clever way to consolidate power and favor certain stakeholders). * Extending contract durations and allowing for more flexible funding arrangements (because who needs accountability when there's money to be made?).

**Affected Parties & Stakeholders:** The usual suspects:

* Researchers and scientists, who will benefit from increased funding and relaxed regulations. * Special interest groups, such as cord blood banks and biotech companies, which will profit from the expanded definition of "high-quality" cord blood units. * Patients and families affected by diseases that may be treated with stem cell therapies (though their interests are merely a convenient pretext for this legislative maneuvering).

**Potential Impact & Implications:** This bill is a textbook example of how to perpetuate bureaucratic inertia while pretending to advance medical research. The increased funding will likely be absorbed by administrative overhead, leaving actual research and therapy development to languish.

The real implications? More money will flow into the pockets of researchers, special interest groups, and politicians who sponsored this bill. Patients and families will continue to wait for meaningful breakthroughs, while the stem cell research community will be treated to another round of self-congratulatory conferences and publications.

In conclusion, HR 5160 is a masterclass in legislative obfuscation, designed to maintain the status quo while creating the illusion of progress. It's a testament to the boundless creativity of politicians and special interest groups when it comes to finding new ways to waste taxpayer money and perpetuate their own power. Bravo, Congress. Bravo.

Generated using Llama 3.1 70B (Dr. Haus personality)

**Summary of HR 5160: Stem Cell Therapeutic and Research Reauthorization Act of 2025**

### 1. Main Purpose & Objectives The main purpose of HR 5160 is to reauthorize the Stem Cell Therapeutic and Research Act of 2005, aiming to advance stem cell research and therapy, particularly focusing on cord blood transplantation. The bill seeks to ensure a sufficient supply of high-quality cord blood units for patients in need of transplants, promote scientific research, and improve the management of the National Cord Blood Inventory.

### 2. Key Provisions & Changes to Existing Law Key provisions include: - Reauthorization of the C.W. Bill Young Cell Transplantation Program with increased funding from $31,009,000 to $33,009,000 for each fiscal year from 2027 through 2031. - Amendments to the cord blood inventory requirements, shifting from a specific target of at least 150,000 new units to maintaining a "sufficient supply" as determined by the Secretary, based on current scientific and clinical evidence. - Enhanced management of the National Cord Blood Inventory to maximize clinical utility, ensure genetic diversity, and promote efficient use of resources. This includes the authority for the Secretary to make determinations regarding the storage of cord blood units and prioritize their collection, retention, or disposition based on scientific, clinical, or operational considerations. - Updates to definitions, including the term "high-quality cord blood unit," which must meet current industry standards and FDA requirements. - Extension of authorization of appropriations for fiscal years 2027 through 2031.

### 3. Affected Parties & Stakeholders Affected parties and stakeholders include: - Patients requiring stem cell transplants, particularly those relying on cord blood donations. - Researchers and scientists involved in stem cell therapeutic research. - Cord blood banks and entities approved by the Secretary for the collection, storage, and distribution of cord blood units. - The healthcare industry, including hospitals and transplant centers. - Regulatory bodies such as the FDA, which will play a role in setting standards for high-quality cord blood units.

### 4. Potential Impact & Implications The potential impact and implications of HR 5160 include: - Enhanced availability and accessibility of high-quality cord blood units for patients in need, potentially improving transplant outcomes. - Advancements in stem cell research due to increased funding and support for the field. - Improved efficiency and effectiveness in the management of the National Cord Blood Inventory, ensuring that resources are utilized optimally. - Potential expansion of genetic diversity within the cord blood inventory, increasing the likelihood of finding suitable matches for patients from diverse ethnic backgrounds. - Economic impacts through job creation and investment in healthcare infrastructure and research facilities.

Overall, HR 5160 aims to support advancements in stem cell therapy and research, with a focus on ensuring that patients have access to life-saving treatments while promoting scientific progress and efficient use of resources.

Generated using Llama 3.1 70B (neutral personality)

Let's dive into this bill, bro! The Stem Cell Therapeutic and Research Reauthorization Act of 2025 is all about reauthorizing the existing program that supports stem cell research and therapy. It's like catching a gnarly wave - we're building on what's already working and making it even better.

**Main Purpose & Objectives:** The main goal, dude, is to keep the momentum going for stem cell research and therapy. This bill aims to reauthorize funding for programs that support cord blood banking, transplantation, and research. It's all about advancing our understanding of stem cells and how they can help people with diseases and injuries.

**Key Provisions & Changes to Existing Law:** Here are some key changes, bro:

* The C.W. Bill Young Cell Transplantation Program gets a funding boost, with $33 million allocated for each fiscal year from 2027 to 2031. * The cord blood inventory is getting an overhaul, with the Secretary of Health and Human Services having more flexibility to manage the supply and ensure it's meeting clinical needs. * There are new definitions and standards for high-quality cord blood units, which will help ensure that patients get the best possible treatment. * Contracts for cord blood banks will be evaluated based on current scientific and clinical info, so we can make sure we're getting the most out of our resources.

**Affected Parties & Stakeholders:** This bill affects a bunch of people, dude:

* Patients who need stem cell transplants or therapy * Researchers working on stem cell projects * Cord blood banks and the companies that collect and store cord blood * The National Institutes of Health (NIH) and other government agencies that fund research

**Potential Impact & Implications:** The impact of this bill could be huge, bro. By reauthorizing funding and updating regulations, we can:

* Advance our understanding of stem cells and how they can help people with diseases and injuries * Improve access to life-saving treatments for patients who need them * Support innovation and job creation in the biotech industry * Ensure that our cord blood inventory is managed efficiently and effectively

It's like riding a wave, dude - we're building on what's already working and pushing forward into new territory. This bill has the potential to make a real difference in people's lives, and that's something to get stoked about!

Generated using Llama 3.1 70B (surfer personality)

**Summary of HR 5160: Stem Cell Therapeutic and Research Reauthorization Act of 2025**

**Main Purpose & Objectives:** The bill's primary objective is to reauthorize funding for the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory. This will ensure continued support for life-saving transplants and advancements in stem cell research.

**Key Provisions & Changes to Existing Law:** Notable changes include:

1. Increased funding for the C.W. Bill Young Cell Transplantation Program, with appropriations of $33,009,000 for each fiscal year from 2027 to 2031. 2. Amendments to the cord blood inventory management, allowing the Secretary to determine a sufficient supply of high-quality cord blood units and transfer units to other qualified banks if necessary. 3. Emphasis on current scientific and clinical information in contract decisions to maximize availability of high-quality cord blood units.

**Affected Parties & Stakeholders:** Key stakeholders include:

1. Patients requiring stem cell transplants 2. Researchers and scientists conducting stem cell research 3. Cord blood banks and transplantation centers 4. Pharmaceutical companies developing stem cell therapies

**Potential Impact & Implications:** The reauthorization of this act will have significant implications for the advancement of stem cell research, cord blood inventory management, and transplantation programs. It is likely to benefit patients in need of life-saving transplants and drive innovation in the field of regenerative medicine.

In terms of monied interests, it's worth noting that pharmaceutical companies, such as Celgene and Gilead Sciences, have a significant stake in stem cell research and may have influenced the bill's provisions. Additionally, organizations like the National Marrow Donor Program and the Cord Blood Association of America may have played a role in shaping the legislation. However, without further information on specific PACs or industry lobby groups backing the bill, it's difficult to provide a more detailed analysis of their influence.

Generated using Llama 3.1 70B (whistleblower personality)

💰 Campaign Finance Network

Rep. Smith, Christopher H. [R-NJ-4]

Congress 119 • 2024 Election Cycle

Total Contributions

$67,100

17 donors

PACs

Organizations

$1,100

Committees

Individuals

$66,000

No PAC contributions found

WALL REPUBLICAN CLUB

1 transaction

$1,100

No committee contributions found

HOLMES, WILLIAM MR.

2 transactions

$6,600

FRANKEL, KEITH MR.

2 transactions

$6,600

CROWLEY-DEANGELIS, DENISE MRS.

2 transactions

$6,600

SAKER, RICHARD MR.

2 transactions

$6,600

CLAYTON, WILLIAM MR.

1 transaction

$3,300

DUNCAN, JAN L. MRS.

1 transaction

$3,300

HARRIS, MARY ELLEN MRS.

1 transaction

$3,300

KOLBER, GEORGE MR.

1 transaction

$3,300

OBERHELMAN, DIANE MRS.

1 transaction

$3,300

DEANGELIS, MARK MR.

1 transaction

$3,300

ADJMI, HARRY MR.

1 transaction

$3,300

ROHAN GREEN, D'ARCY MRS.

1 transaction

$3,300

FRANKEL, TAMMY MRS.

1 transaction

$3,300

HILL, VERNON

1 transaction

$3,300

SAKER, LAURA MRS.

1 transaction

$3,300

SUN, ROBERT X. MR.

1 transaction

$3,300

Cosponsors & Their Campaign Finance

This bill has 10 cosponsors. Below are their top campaign contributors.

Rep. Matsui, Doris O. [D-CA-7]

ID: M001163

Top Contributors

SOCIETY OF INTERVENTIONAL RADIOLOGY POLITICAL ACTION COMMITTEE

PACFAIRFAX, VA

$2,500

Feb 7, 2023

MORONGO BAND OF MISSION INDIANS

OrganizationBANNING, CA

$2,000

Mar 10, 2023

KINNEY, MARY

MGK STYLE • STYLIST/CEO

IndividualSACRAMENTO, CA

$3,300

Oct 30, 2024

KONG, MINDY

N/A • HOMEMAKER

IndividualSACRAMENTO, CA

$3,300

Oct 25, 2024

TSAKOPOULOS, KATINA

SELF-EMPLOYED • SOMATIC EXPERIENCING PRACTITIONER

IndividualRANCHO SANTA FE, CA

$3,300

Nov 1, 2024

TSAKOPOULOS, SOFIA

N/A • HOMEMAKER

IndividualSACRAMENTO, CA

$3,300

Nov 1, 2024

VISMARA, LOUIS A.

IndividualSACRAMENTO, CA

$3,300

Nov 1, 2024

WAGNER, BELAN KIRK

WAGNER KIRKMAN BLAINE KLOMPARENS • ATTORNEY

IndividualMATHER, CA

$3,300

May 30, 2023

KELLEY, LARRY D.

MCCLELLAN PARK • REAL ESTATE

IndividualMCCLELLAN, CA

$3,300

May 11, 2023

FRIEDMAN, MARK L.

FULCRUM PROPERTY GROUP • REAL ESTATE DEVELOPER

IndividualSACRAMENTO, CA

$3,300

Jun 14, 2023

Rep. Bilirakis, Gus M. [R-FL-12]

ID: B001257

Top Contributors

COOL MASTER PRO LLC

OrganizationTAMPA, FL

$6,600

Mar 8, 2023

ARTECHE, LEON

V-ME MEDIA INC. • CFO

IndividualDORAL, FL

$5,000

Jan 18, 2024

OF FLORIDA, SEMINOLE TRIBE

EMPLOYEE RECOGNIZED TRIBE

IndividualHOLLYWOOD, FL

$3,300

Aug 2, 2024

LAGOS, JAMES H.

LAGOS LAGOS, PLL • ATTORNEY

IndividualSPRINGFIELD, OH

$3,300

Sep 9, 2024

RICE, WILLIAM LLOYD

FALFURRIAS CAPITAL PARTNERS

IndividualMINT HILL, NC

$3,300

Sep 30, 2024

WANEK, RON

ASHLEY FURNITURE INDUSTRIES, INC • CHAIRMAN OF THE BOARD

IndividualTAMPA, FL

$3,300

Oct 17, 2024

WANEK, TODD

ASHLEY FURNITURE • CEO

IndividualTAMPA, FL

$3,300

Oct 17, 2024

WANEK, JOYCE

N/A • N/A

IndividualTAMPA, FL

$3,300

Oct 18, 2024

WANEK, KAREN

SUPERIOR FRESH • OWNER

IndividualTAMPA, FL

$3,300

Oct 17, 2024

HEPSCHER, WILLIAM S

RX MANAGE USA • BUSINESS OWNER

IndividualTAMPA, FL

$3,300

Oct 30, 2024

Rep. Pingree, Chellie [D-ME-1]

ID: P000597

Top Contributors

FEDERATED INDIANS OF GRATON RANCHERIA

OrganizationROHNERT PARK, CA

$5,000

Aug 6, 2024

MASHANTUCKET PEQUOT TRIBAL NATION

OrganizationMASHANTUCKET, CT

$3,300

Oct 30, 2024

SHAKOPEE MDEWAKANTON SIOUX COMMUNITY

OrganizationPRIOR LAKE, MN

$3,300

Jun 5, 2023

CHEROKEE NATION

OrganizationTAHLEQUAH, OK

$3,300

Jun 11, 2024

SHAKOPEE MDEWAKANTON SIOUX COMMUNITY

OrganizationPRIOR LAKE, MN

$3,300

Jun 18, 2024

MOORETOWN RANCHERIA

OrganizationOROVILLE, CA

$3,300

Sep 30, 2024

FEDERATED INDIANS OF GRATON RANCHERIA

OrganizationROHNERT PARK, CA

$1,700

Sep 19, 2024

CHOCTAW NATION OF OKLAHOMA

OrganizationDURANT, OK

$1,650

Sep 30, 2023

AK-CHIN INDIAN COMMUNITY

OrganizationMARICOPA, AZ

$1,000

Oct 18, 2024

MUSCOGEE CREEK NATION

OrganizationOKMULGEE, OK

$1,000

Dec 26, 2023

Rep. Tenney, Claudia [R-NY-24]

ID: T000478

Top Contributors

WINRED EARMARKS

PACARLINGTON, VA

$27,879

Oct 22, 2024

WINRED EARMARKS

PACARLINGTON, VA

$21,566

Oct 29, 2024

WINRED EARMARKS

PACARLINGTON, VA

$10,970

Nov 25, 2024

WINRED EARMARKS

PACARLINGTON, VA

$5,493

Nov 19, 2024

SAN MANUEL BAND OF MISSION INDIANS

OrganizationLOS ANGELES, CA

$2,000

Nov 5, 2024

MORONGO BAND OF MISSION INDIANS

OrganizationBANNING, CA

$2,000

Jun 18, 2024

SANTA YNEZ BAND OF MISSION INDIANS

OrganizationSANTA YNEZ, CA

$2,000

Jun 18, 2024

MORONGO BAND OF MISSION INDIANS

OrganizationBANNING, CA

$1,000

Mar 31, 2023

TEXTOR, DONALD

RETIRED • RETIRED

IndividualLOCUST VALLEY, NY

$13,200

Apr 17, 2024

WINE, SCOTT

POLARIS • CEO

IndividualEXCELSIOR, MN

$6,600

Sep 30, 2024

Rep. Mfume, Kweisi [D-MD-7]

ID: M000687

Top Contributors

TABORN, TYRONE D.

IndividualREISTERSTOWN, MD

$5,000

Jul 31, 2024

BRONFEIN, MICHAEL

CURIO WELLNESS • CEO

IndividualOWINGS MILLS, MD

$3,300

Oct 17, 2024

SEIBEL, MICHAEL

Y COMBINATOR • INVESTOR

IndividualSAN FRANCISCO, CA

$3,300

Oct 17, 2024

JOHNSON, ROBERT

THE RLJ COMPANIES • EXECUTIVE

IndividualBETHESDA, MD

$3,300

Oct 22, 2024

JOSEPH, MARK K.

N/A • RETIRED

IndividualBALTIMORE, MD

$3,300

Oct 22, 2024

JOHNSON, ROBERT

THE RLJ COMPANIES • EXECUTIVE

IndividualBETHESDA, MD

$3,300

Nov 9, 2023

TABORN, TYRONE D.

CAREER COMMUNICATIONS GROUP • METAVERSE CREATOR

IndividualREISTERSTOWN, MD

$3,300

Oct 31, 2023

FISCHER, SOLOMON

FISCHER ROOFING • ROOFER

IndividualLAKEWOOD, NJ

$3,000

Oct 7, 2024

TABORN, TYRONE D.

CAREER COMMUNICATIONS GROUP • METAVERSE CREATOR

IndividualREISTERSTOWN, MD

$3,000

Jul 27, 2024

BEREANO, BRUCE C.

SELF-EMPLOYED • GOVERNMENT RELATIONS CONSULTANT

IndividualANNAPOLIS, MD

$2,500

Oct 23, 2024

Rep. Fischbach, Michelle [R-MN-7]

ID: F000470

Top Contributors

CHEROKEE NATION

OrganizationTAHLEQUAH, OK

$2,500

Dec 18, 2023

SHAKOPEE MDEWAKANTON SIOUX COMMUNITY

OrganizationPRIOR LAKE, MN

$1,650

Nov 3, 2023

SHAKOPEE MDEWAKANTON SIOUX COMMUNITY

OrganizationPRIOR LAKE, MN

$1,650

Jun 17, 2024

SHAKOPEE MDEWAKANTON SIOUX COMMUNITY

OrganizationPRIOR LAKE, MN

$1,650

Jun 17, 2024

SANTA YNEZ BAND OF MISSION INDIANS

OrganizationSANTA YNEZ, CA

$1,500

Mar 19, 2024

MS BAND OF CHOCTAW INDIANS

OrganizationCHOCTAW, MS

$1,000

Nov 5, 2024

MORONGO BAND OF MISSION INDIANS

OrganizationBANNING, CA

$1,000

Mar 27, 2023

SALT RIVER PIMA MARICOPA INDIAN COMMUNITY

OrganizationSCOTTSDALE, AZ

$1,000

Mar 31, 2023

MORONGO BAND OF MISSION INDIANS

OrganizationBANNING, CA

$1,000

Feb 27, 2024

SANTA YNEZ BAND OF MISSION INDIANS

OrganizationSANTA YNEZ, CA

$1,000

Jun 28, 2023

Rep. Dingell, Debbie [D-MI-6]

ID: D000624

Top Contributors

MATCH-E-BE-NASH-SHE-WISH BAND OF POTTAWATOMI INDIANS

OrganizationDORR, MI

$3,300

Dec 13, 2023

NOTTAWASEPPI HURON BAND OF THE POTAWATOMI

OrganizationFULTON, MI

$3,300

Mar 28, 2024

MATCH-E-BE-NASH-SHE-WISH BAND OF POTTAWATOMI INDIANS

OrganizationDORR, MI

$3,300

Oct 16, 2024

FORD, CYNTHIA

NA • CIVIC PHILANTHROPIST

IndividualGROSSE POINTE FARMS, MI

$3,300

Oct 14, 2024

FORD, EDSEL B. II

FORD MOTOR COMPANY • CONSULTANT

IndividualGROSSE POINTE FARMS, MI

$3,300

Oct 14, 2024

MEIJER, HENDRIK

MEIJER, INC. • EXECUTIVE CHAIRMAN

IndividualGRAND RAPIDS, MI

$3,300

Oct 25, 2024

CARTER ALTMAN, LYNDA

SELF EMPLOYED • MUSICIAN

IndividualNEW YORK, NY

$3,300

Nov 6, 2023

DEBBANE, RAYMOND

THE INVUS GROUP • CEO

IndividualGREENWICH, CT

$3,300

Dec 4, 2023

FARES, NIJAD

LINK • INVESTOR

IndividualHOUSTON, TX

$3,300

Nov 30, 2023

III, WILLIAM H. GATES

BREAKTHROUGH ENERGY & BILL & MELINDA G • PHILANTHROPIST

IndividualREDMOND, WA

$3,300

Oct 19, 2023

Rep. Gottheimer, Josh [D-NJ-5]

ID: G000583

Top Contributors

AMERICAN EXPRESS

OrganizationNEWARK, NJ

$22,941

Apr 12, 2024

AMERICAN EXPRESS

OrganizationNEWARK, NJ

$10,621

May 10, 2024

PAYROLL DATA PROCESSING

OrganizationTAMPA, FL

$6,337

May 15, 2024

PAYROLL DATA PROCESSING

OrganizationTAMPA, FL

$6,337

Apr 15, 2024

PAYROLL DATA PROCESSING

OrganizationTAMPA, FL

$6,337

Apr 30, 2024

PAYROLL DATA PROCESSING

OrganizationTAMPA, FL

$5,751

Apr 1, 2024

EASTERN BAND OF CHEROKEE INDIANS

OrganizationCHEROKEE, NC

$3,300

Oct 22, 2024

SEKAS LAW GROUP LLC

OrganizationENGLEWOOD CLIFFS, NJ

$1,500

Apr 12, 2024

SANDOR F. GENET & ASSOCIATES, P.A.

OrganizationNORTH MIAMI BEACH, FL

$250

Apr 12, 2024

FIRESTONE MILKEN, SARAH

NOT EMPLOYED • NOT EMPLOYED

IndividualPACIFIC PALISADES, CA

$13,200

Jul 2, 2024

Rep. Aderholt, Robert B. [R-AL-4]

ID: A000055

Top Contributors

CHALMERS, ADAMS, BACKER & KAUFMAN LLC

OrganizationJOHNS CREEK, GA

$2,900

Mar 7, 2023

IMPACT JOURNALS

OrganizationORCHARD PARK, NY

$1,200

Jun 4, 2023

SUIT, LLC

OrganizationATTALLA, AL

$500

Jun 10, 2023

ROBIN, CRAIG A.

EO SOLUTIONS • CEO

IndividualALBUQUERQUE, NM

$6,600

Nov 13, 2023

HOKR, BRETT H.

EO SOLUTIONS • CTO

IndividualHUNTSVILLE, AL

$6,600

Nov 13, 2023

LESSMANN, KURT M.

TRIDEUM • CTO

IndividualMADISON, AL

$6,600

Oct 2, 2023

KHALILI, KAVEH

EO SOLUTIONS • COO

IndividualBOULDER CITY, NV

$6,600

Nov 13, 2023

BUFFALOE, STEPHANIE

HOME INSTEAD TUSCALOOSA • OWNER

IndividualTUSCALOOSA, AL

$6,600

Nov 15, 2023

COLLAZO, FRANCISCO JOSE

COLSA CORP • PRESIDENT/CEO

IndividualHUNTSVILLE, AL

$6,600

Oct 2, 2023

HUNT, RAY L.

HUNT CONSOLIDATED INC. • PRESIDENT

IndividualDALLAS, TX

$6,600

Feb 21, 2024

Rep. Malliotakis, Nicole [R-NY-11]

ID: M000317

Top Contributors

M&T BANK

OrganizationMOUNT KISCO, NY

$118

Sep 21, 2024

M&T BANK

OrganizationMOUNT KISCO, NY

$101

Sep 21, 2024

SIDIROPOULOS, JIM MR.

DELPHI PH • CONTRACTOR

IndividualSTATEN ISLAND, NY

$5,600

Jul 23, 2024

BERGER, RICHARD MR.

RETIRED • RETIRED

IndividualHOBOKEN, NJ

$5,000

May 17, 2024

LOEB, JOHN L. MR. JR

RETIRED • RETIRED

IndividualPURCHASE, NY

$5,000

Apr 22, 2024

BAUMRIND, MARTIN M. MR.

SELF • LANDLORD

IndividualBROOKLYN, NY

$5,000

Sep 16, 2024

DUIT, JAMES A

CONTRIBUTION OF CONCEPTION LLC • EXEC

IndividualEDMOND, OK

$3,300

Nov 5, 2024

DUIT, PAMELA A

CONTRIBUTION OF CONCEPTION LLC • EXEC

IndividualEDMOND, OK

$3,300

Nov 5, 2024

LAUDER, RONALD S.

SELF EMPLOYED • BUSINESSMAN

IndividualNEW YORK, NY

$3,300

Oct 28, 2024

BANKE, BARBARA R. MS.

CHAIRMAN • JACKSON FAMILY WINES

IndividualGEYSERVILLE, CA

$3,300

Nov 17, 2023

Donor Network - Rep. Smith, Christopher H. [R-NJ-4]

Show Also Donated To

PACs

Organizations

Individuals

Politicians

Hub layout: Politicians in center, donors arranged by type in rings around them.

Showing 19 nodes and 22 connections

Total contributions: $22

Top Donors - Rep. Smith, Christopher H. [R-NJ-4]

Showing top 17 donors by contribution amount

1 Org16 Individuals

Industry Impact

Which industries are materially affected by specific provisions in this bill. 2 helped.

+Biotech & Researchconfidence 0.90
Section 2 reauthorizes funding for the C.W. Bill Young Cell Transplantation Program, increasing appropriations from $31,009,000 to $33,009,000 for FY 2027-2031, providing a clear benefit to biotech and research firms involved in stem cell therapeutics.
+Hospitals & Health Systemsconfidence 0.85
Section 3 extends the cord blood inventory deadline from 2026 to 2031, supporting hospitals and health systems that collect, store, and use cord blood for transplants, representing a market expansion.

Project 2025 Policy Matches

This bill shows semantic similarity to the following sections of the Project 2025 policy document.AI-enhanced analysis provides detailed alignment ratings.

Department of Health and Human Services

Strong

Vector: 61%

Pages: 530-532AI Enhanced

AI Analysis:

"HR 5160 advances HHS's strategic goal of protecting and strengthening equitable access to high-quality, affordable healthcare by expanding the supply and diversity of cord blood units, thereby improving transplant outcomes for underserved populations and supporting innovative stem cell research."

Key themes:equitable access to healthcarehigh-quality affordable healthcareunderserved communitiesmedical research innovationgenetic diversity in healthcare resources

— 498 — Mandate for Leadership: The Conservative Promise ENDNOTES 1. U.S. Department of Health and Human Services, Strategic Plan, FY 2018–2022, p. 50, https://aspe.hhs.gov/ sites/default/files/documents/feac346aca967bfadc446398679e14ec/hhs-strategic-plan-fy-2018-2022.pdf (accessed February 7, 2023). 2. “Strategic Goal 1: Protect and Strengthen Equitable Access to High Quality and Affordable Healthcare” in ibid. “In the context of HHS, this Strategic Plan adopts the definition of underserved communities listed in Executive Order 13985: Advancing Racial Equity and Support for Underserved Communities through the Federal Government to refer to ‘populations sharing a particular characteristic, as well as geographic communities, who have been systematically denied a full opportunity to participate in aspects of economic, social, and civic life’; this definition includes individuals who belong to underserved communities that have been denied such treatment, such as Black, Latino, and Indigenous and Native American persons, Asian Americans and Pacific Islanders and other persons of color; members of religious minorities; lesbian, gay, bisexual, transgender, and queer (LGBTQ+) persons; persons with disabilities; persons who live in rural areas; and persons otherwise adversely affected by persistent poverty or inequality. Individuals may belong to more than one underserved community and face intersecting barriers. This definition applies to the terms underserved communities and underserved populations throughout this Strategic Plan.” Ibid. Emphasis in original. 3. Karen Weintraub, “Americans’ Life Expectancy Continues to Fall, Erasing Health Gains of the Last Quarter Century,” USA Today, December 22, 2022, https://www.usatoday.com/story/news/health/2022/12/22/us-life- expectancy-continues-fall-erasing-25-years-health-gains/10937418002/ (accessed February 6, 2023). 4. Apoorva Mandavilli, “The C.D.C. Isn’t Publishing Large Portions of the Data It Collects,” The New York Times, updated February 22, 2022, https://www.congress.gov/117/meeting/house/114450/documents/HHRG-117- IF02-20220302-SD004.pdf (accessed March 22, 2023). 5. Zachary B. Sluzala and Edmund F. Haislmaier, “Lessons from COVID-19: How Policymakers Should Reform the Regulation of Clinical Testing,” Heritage Foundation Backgrounder No. 3696, March 28, 2022, https://www. heritage.org/public-health/report/lessons-covid-19-how-policymakers-should-reform-the-regulation-clinical. 6. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, “Centers for Disease Control and Prevention (C),” https://www.cdc.gov/maso/pdf/cdcmiss.pdf (March 16, 2023). 7. Judith Garber, “CDC ‘Disclaimers’ Hide Financial Conflicts of Interest,” Lown Institute Accountability Blog, November 6, 2019, https://lowninstitute.org/cdc-disclaimers-hide-financial-conflicts-of-interest/ (accessed February 6, 2023). See also U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, “CDC Foundation Active Programs (October 1, 2014–September 30, 2015),” https://www. cdcfoundation.org/sites/default/files/upload/pdf/CDCFoundation-ActivePrograms-FY2015.pdf (accessed February 7, 2023); “CDC Active Programs (October 1, 2015–September 30, 2016),” https://www.cdcfoundation. org/sites/default/files/upload/pdf/CDCFoundation-ActivePrograms-FY2016.pdf (accessed February 7, 2023); “CDC Foundation Active Programs (October 1, 2016–September 30, 2017),” https://www.cdcfoundation.org/ sites/default/files/upload/pdf/CDCFoundation-ActivePrograms-FY2017.pdf (accessed February 7, 2023); “CDC Foundation Active Programs (October 1, 2017–September 30, 2018),” https://www.cdcfoundation.org/sites/default/ files/upload/pdf/CDCFoundation-ActivePrograms-FY2018.pdf (accessed February 7, 2023); “CDC Foundation Active Programs, October 1, 2018–September 30, 2019,” https://www.cdcfoundation.org/sites/default/files/upload/ pdf/CDCFoundation-ActivePrograms-FY2019.pdf (accessed February 7, 2023); “CDC Foundation Active Programs, October 1, 2029–September 30, 2020,” https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY20?inline (accessed February 7, 2023); and “CDC Foundation Active Programs, October 1, 2020–September 30, 2021,” https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline (accessed February 7, 2023). 8. Joel White and Doug Badger, “In Order to Defeat COVID-19, the Federal Government Must Modernize Its Public Health Data,” Heritage Foundation Backgrounder No. 3527, September 3, 2020, https://www.heritage. org/sites/default/files/2020-09/BG3527_0.pdf. 9. S. 15, Ensuring Accurate and Complete Abortion Data Reporting Act of 2023, 118th Congress, introduced January 23, 2023, https://www.congress.gov/118/bills/s15/BILLS-118s15is.pdf (accessed March 22, 2023), and H.R. 632, Ensuring Accurate and Complete Abortion Data Reporting Act of 2023, 118th Congress, introduced January 30, 2023, https://www.congress.gov/118/bills/hr632/BILLS-118hr632ih.pdf (accessed March 22, 2023). 10. Doug Badger, “How Congress Can Make Real Progress on Drug Prices,” Heritage Foundation Issue Brief No. 5016, December 9, 2019, https://www.heritage.org/sites/default/files/2019-12/IB5016_1.pdf. — 499 — Department of Health and Human Services 11. Sluzala and Haislmaier, “Lessons From COVID-19: How Policymakers Should Reform the Regulation of Clinical Testing.” 12. Ibid. 13. H.R. 5471, Clinical Laboratory Improvement Amendments of 1988, Public Law No. 100-578, 100th Congress, October 31, 1988, https://uscode.house.gov/statutes/pl/100/578.pdf (accessed March 17, 2023). 14. Sluzala and Haislmaier, “Lessons From COVID-19: How Policymakers Should Reform the Regulation of Clinical Testing.” 15. Edmund F. Haislmaier, “Ensuring Americans’ Access to Pharmaceuticals: A Primer and Road Map for Policymakers,” Heritage Foundation Backgrounder No. 3545, October 20, 2020, https://www.heritage.org/ sites/default/files/2020-10/BG3545.pdf. 16. 18 U.S.C. 1461, https://www.law.cornell.edu/uscode/text/18/1461 (accessed March 16, 2023), and 18 U.S.C. 1462, https://www.law.cornell.edu/uscode/text/18/1462 (accessed March 16, 2023). 17. H.R. 1308, Religious Freedom Restoration Act of 1993, Public Law No. 103-141, 103rd Congress, November 16, 1993, https://www.congress.gov/103/statute/STATUTE-107/STATUTE-107-Pg1488.pdf (accessed March 18, 2023). 18. Charles Piller, “Is FDA’s Revolving Door Open Too Wide?” Science, Vol. 361, No. 6397 (July 6, 2018), p. 21, https://www.science.org/doi/epdf/10.1126/science.361.6397.21 (accessed February 6, 2023). 19. Joel Achenbach, “NIH Halts $100 Million Study of Moderate Drinking That Is Funded by Alcohol Industry,” The Washington Post, May 17, 2018, https://www.washingtonpost.com/news/to-your-health/wp/2018/05/17/nih- halts-controversial-study-of-moderate-drinking/ (accessed February 6, 2023). 20. Alexander Tin, “Moderna Offers NIH Co-ownership of COVID Vaccine Patent amid Dispute with Government,” CBS News, November 15, 2021, https://www.cbsnews.com/news/moderna-covid-vaccine-patent-dispute- national-institutes-health/ (accessed February 6, 2023). 21. Informed Consent Action Network, “NIH Officials Profiting from COVID-19 Vaccine,” June 3, 2021, https://www. icandecide.org/nih-officials-profiting-from-covid-19-vaccine/ (accessed February 6, 2023). 22. Adam Andrzejewski, “Substack Investigation: Fauci’s Royalties and the $350 Million Royalty Payment Stream HIDDEN by NIH,” Open the Books Substack, May 9, 2022, https://openthebooks.substack. com/p/faucis-royalties-and-the-350-million?utm_source=/profile/24758236-adam-andrzejewski&utm_ medium=reader2&s=w (accessed February 6, 2023). 23. Robert E. Moffit, “Time to Reverse Hospital Market Consolidation,” Heritage Foundation Commentary, January 5, 2022, https://www.heritage.org/health-care-reform/commentary/time-reverse-hospital-market-consolidation. 24. H.R. 3590, Patient Protection and Affordable Care Act, Public Law No. 111-148, 111th Congress, March 23, 2021, https://www.congress.gov/111/plaws/publ148/PLAW-111publ148.pdf (accessed March 16, 2023). 25. Brian J. Miller, Robert E. Moffit, James Ficke, Joseph Marine, and Jesse Ehrenfeld, “Reversing Hospital Consolidation: The Promise of Physician-Owned Hospitals,” Health Affairs Forefront, April 12, 2021, https:// www.healthaffairs.org/do/10.1377/forefront.20210408.980640/ (accessed February 13, 2023). 26. Robert E. Moffit, “Medicare’s Future: Challenges and Opportunities,” testimony before the Special Committee on Aging, U.S. Senate, November 21, 2022, https://www.heritage.org/testimony/medicares-future-challenges- and-opportunities. 27. 42 U.S. Code § 256b, https://www.law.cornell.edu/uscode/text/42/256b (accessed March 16, 2023). 28. H.R. 3590, Patient Protection and Affordable Care Act, § 3022. 29. H.R. 5376, Inflation Reduction Act of 2022, Public Law No. 117-169, 117th Congress, August 16, 2022, https:// www.congress.gov/117/plaws/publ169/PLAW-117publ169.pdf (accessed March 16, 2023). 30. Robert E. Moffit, “Reducing Patient Access to New Medications Is the Left’s Latest Medicare Price-Fixing Scheme,” Heritage Foundation Commentary, July 22, 2022, https://www.heritage.org/medicare/commentary/ reducing-patient-access-new-medications-the-lefts-latest-medicare-price-fixing, and Badger, “How Congress Can Make Real Progress on Drug Prices.” 31. Nina Owcharenko Schaefer, “Medicaid at 55: Understanding the Design, Trends, and Reforms Needed to Improve the Health Care Safety Net,” Heritage Foundation Backgrounder No. 3604, April 14, 2021, https:// www.heritage.org/sites/default/files/2021-04/BG3604_0.pdf, and Brian C. Blase, “Punishing Conservative States: Payment Cuts to Hospitals Where Federal Spending Is Already Low,” Paragon Health Institute, December 2021, https://paragoninstitute.org/wp-content/uploads/2022/06/Punishing-Conservative-States- HTML.html (accessed February 13, 2023).

Department of Health and Human Services

Minimal

Vector: 62%

Pages: 533-535AI Enhanced

AI Analysis:

"HR 5160 focuses on reauthorizing stem cell research and cord blood inventory programs, while the Project 2025 HHS section references policies related to abortion, conscience protections, gender-affirming care, and civil rights regulations—none of which are thematically connected to the bill's objectives."

— 501 — Department of Health and Human Services 54. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, Office of Civil Rights, and Office of the Secretary, “Special Responsibilities of Medicare Hospitals in Emergency Cases and Discrimination on the Basis of Disability in Critical Health and Human Service Programs or Activities,” draft of Proposed Rule, January 14, 2021, https://www.hhs.gov/sites/default/files/infants-nprm.pdf (accessed March 17, 2023). 55. H.R. 26, Born-Alive Abortion Survivors Protection Act, 118th Congress, introduced January 9, 2023, https:// www.congress.gov/118/bills/hr26/BILLS-118hr26pcs.pdf (accessed March 17, 2023). 56. H.R. 7, No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2023, 118th Congress, introduced January 9, 2023, https://www.congress.gov/118/bills/hr7/BILLS-118hr7ih.pdf (accessed March 17, 2023). 57. S. 401, Conscience Protection Act of 2021, 117th Congress, introduced February 24, 2021, https://www.congress. gov/117/bills/s401/BILLS-117s401is.pdf (accessed March 17, 2023). 58. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, and Office of the Secretary, “Nondiscrimination in Health Programs and Activities,” Notice of Proposed Rulemaking; Notice of Tribal Consultation, Federal Register, Vol. 87, No. 149 (August 4, 2022), pp. 47824–47920, https://www.govinfo. gov/content/pkg/FR-2022-08-04/pdf/2022-16217.pdf (accessed March 17, 2023). 59. Ibid., p. 47916. 60. The regulation was not finalized before the end of the Administration. U.S. Department of Agriculture, Food and Nutrition Services, “Revision of Categorical Eligibility in the Supplemental Nutrition Assistance Program (SNAP),” Proposed Rule, Federal Register, Vol. 84, No. 142 (July 24, 2019), pp. 35570–55581, https:// www.federalregister.gov/documents/2019/07/24/2019-15670/revision-of-categorical-eligibility-in-the- supplemental-nutrition-assistance-program-snap (accessed March 17, 2023). 61. 45 Code of Federal Regulations § 75.300(c) and (d), https://www.ecfr.gov/current/title-45/subtitle-A/ subchapter-A/part-75/subpart-D/subject-group-ECFR911e5e1a30bfbcb/section-75.300 (accessed March 17, 2023). 62. H.R. 1750, Child Welfare Provider Inclusion Act of 2021, 117th Congress, introduced March 10, 2021, https:// www.congress.gov/117/bills/hr1750/BILLS-117hr1750ih.pdf (accessed March 17, 2023), and S. 656, Child Welfare Provider Inclusion Act of 2021, 117th Congress, introduced March 10, 2021, https://www.congress.gov/117/bills/ s656/BILLS-117s656is.pdf (accessed March 17, 2023). 63. S. 3949, Trafficking Victims Protection Reauthorization Act of 2022, Public Law No. 117-348, 117th Congress, January 25, 2023, https://www.congress.gov/117/plaws/publ348/PLAW-117publ348.pdf (accessed March 17, 2023). 64. Kelsey Y. Santamaria, “Child Migrants at the Border: The Flores Settlement Agreement and Other Legal Developments,” Congressional Research Service In Focus No. IF11799, April 1, 2021, https://crsreports.congress. gov/product/pdf/IF/IF11799 (accessed March 17, 2023). 65. Report, Building a Happy Home: Marriage Education as a Tool to Strengthen Families, Social Capital Project Report No. 1-22, March 2022, p. 17, https://www.jec.senate.gov/public/_cache/files/3d102525-6f0d-48ed- 92f4-d71edd468ad6/building-a-happy-home.pdf (accessed March 17, 2023). The cover of the report reflects that the Social Capital Project is “[a] project of the Joint Economic Committee – Republicans.” 66. See, for example, Alan J. Hawkins, “Are Federally Supported Relationship Education Programs for Lower-Income Individuals and Couples Working? A Review of Evaluation Research,” American Enterprise Institute, September 2019, https://www. congress.gov/117/plaws/publ228/PLAW-117publ228.pdf (accessed March 17, 2023). 67. H.R. 8404, Respect for Marriage Act, Public Law No. 117-228, 117th Congress, December 13, 2022, https://www. congress.gov/117/plaws/publ228/PLAW-117publ228.pdf (accessed March 17, 2023). 68. Madison Marino, “Over 1,000 Safety Violations Mar Head Start. Children Deserve Better,” Heritage Foundation Commentary, November 10, 2022, https://www.heritage.org/education/commentary/over-1000-safety- violations-mar-head-start-children-deserve-better. 69. American Hospital Association v. Becerra, 596 U.S. ___ (2022), https://www.supremecourt.gov/ opinions/21pdf/20-1114_09m1.pdf (accessed March 17, 2023). 70. U.S. Department of the Treasury, Internal Revenue Service; U.S. Department of Labor, Employee Benefits Security Administration; and U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, “Coverage of Certain Preventive Services Under the Affordable Care Act,” Notice of Proposed Rulemaking, Federal Register, Vol. 88, No. 22 (February 2, 2023), pp. 7236–7281, https://www. govinfo.gov/content/pkg/FR-2023-02-02/pdf/2023-01981.pdf (accessed March 17, 2023). — 502 — Mandate for Leadership: The Conservative Promise 71. 42 U.S. Code § 238n, https://www.law.cornell.edu/uscode/text/42/238n (accessed March 17, 2023). 72. U.S. Department of Health and Human Services, Health Resources and Services Administration, “Early Childhood Health,” last reviewed October 2022, https://mchb.hrsa.gov/programs-impact/focus-areas/early- childhood-health (accessed March 17, 2023). 73. American Pregnancy Association, “Having a Doula—What Are the Benefits?” https://americanpregnancy. org/healthy-pregnancy/labor-and-birth/having-a-doula/#:~:text=Other%20studies%20have%20shown%20 that%20having%20a%20doula,massage%20to%20reduce%20stress%20and%20anxiety%20during%20labor (accessed March 17, 2023). 74. S. 2372, VA MISSION [Maintaining Internal Systems and Strengthening Integrated Outside Networks] Act of 2018, Public Law No. 115-182, 115th Congress, June 6, 2018, https://www.congress.gov/115/plaws/publ182/ PLAW-115publ182.pdf (accessed March 17, 2023). 75. U.S. Department of Health and Human Services, “Securing Updated and Necessary Statutory Evaluations Timely,” Final Rule, Federal Register, Vol. 86, No. 11 (January 19, 2021), pp. 5694–5764, https://www.govinfo. gov/content/pkg/FR-2021-01-19/pdf/2021-00597.pdf (accessed March 22, 2023). 76. U.S. Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health, “Compliance with Statutory Program Integrity Requirements,” Final Rule, Federal Register, Vol. 84, No. 42 (March 4, 2029), pp. 7714–7791, https://www.govinfo.gov/content/pkg/FR-2019-03-04/pdf/2019-03461.pdf (accessed March 18, 2023). 77. U.S. Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health, “Ensuring Access to Equitable, Affordable, Client-Centered, Quality Family Planning Services,” Final Rule, Federal Register, Vol. 86, No. 192 (October 7, 2021), pp. 56144–56180, https://www.govinfo.gov/content/ pkg/FR-2021-10-07/pdf/2021-21542.pdf (accessed March 18, 2023). 78. S. 624, Title X Abortion Provider Prohibition Act, 118th Congress, introduced March 2, 2023, https://www. congress.gov/118/bills/s624/BILLS-118s624is.pdf (accessed March 18, 2023). 79. 50 U.S. Code Chapter 55, https://www.law.cornell.edu/uscode/text/50/chapter-55 (accessed March 22, 2023). 80. 18 U.S. Code § 13, https://www.law.cornell.edu/uscode/text/18/13 (accessed March 18, 2023). 81. Bowen v. American Hospital Association, 476 U.S. 610 (1986), https://tile.loc.gov/storage-services/service/ll/ usrep/usrep476/usrep476610/usrep476610.pdf (accessed 22, 2023). 82. U.S. Department of Health and Human Services, Office of the Secretary, “Notification of Interpretation and Enforcement of Section 1557 of the Affordable Care Act and Title IX of the Education Amendments of 1972,” Federal Register, Vol. 86, No. 99 (May 25, 2021), pp. 27984–27985, https://www.govinfo.gov/content/pkg/FR- 2021-05-25/pdf/2021-10477.pdf (accessed March 18, 2023). 83. U.S. Department of Health and Human Services, Office for Civil Rights, “HHS Notice and Guidance on Gender Affirming Care, Civil Rights, and Patient Privacy,” March 2, 2022, https://www.hhs.gov/sites/default/files/hhs- ocr-notice-and-guidance-gender-affirming-care.pdf (accessed March 18, 2023). 84. Heckler v. Chaney, 420 U.S. 821 (1985), https://caselaw.findlaw.com/us-supreme-court/470/821.html (accessed March 18, 2022). 85. U.S. Department of Health and Human Services, Office for Civil Rights, “Guidance to Nation’s Retail Pharmacies: Obligations Under Federal Civil Rights Laws to Ensure Access to Comprehensive Reproductive Health Care Services,” content last reviewed July 14, 2022, https://www.hhs.gov/civil-rights/for-individuals/ special-topics/reproductive-healthcare/pharmacies-guidance/index.html (accessed March 18, 2023). 86. H.R. 3103, “Health Insurance and Portability and Accountability Act of 1996, Public Law No. 104-191, 104th Congress, August 21, 1996, https://www.congress.gov/104/plaws/publ191/PLAW-104publ191.pdf (accessed March 18, 2023). 87. U.S. Department of Human Services, “HIPAA Privacy Rule and Disclosures of Information Relating to Reproductive Health Care,” content last reviewed June 29, 2022, (accessed March 18, 2023). See also “Protecting the Privacy and Security of Your Health Information When Using Your Personal Cell Phone or Tablet,” content last reviewed June 29, 2022, https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/ cell-phone-hipaa/index.html (accessed March 18, 2023).

Department of Health and Human Services

Minimal

Vector: 60%

Pages: 533-535AI Enhanced

AI Analysis:

"HR 5160 focuses on reauthorizing stem cell research and cord blood inventory programs, while the Project 2025 HHS section emphasizes Medicaid reform, abortion policy, and healthcare regulation—there is no substantive thematic or policy overlap between the two."

— 500 — Mandate for Leadership: The Conservative Promise 32. Owcharenko Schaefer, “Medicaid at 55: Understanding the Design, Trends, and Reforms Needed to Improve the Health Care Safety Net.” 33. Brian Blase, “Managed Care in Medicaid: Need for Oversight, Accountability, and Reform,” Paragon Health Institute Policy Brief, October 13, 2022, https://paragoninstitute.org/wp-content/uploads/2022/10/20221012- Managed-Care-in-Medicaid-Need-for-Oversight-Accountability-and-Reform-FOR-DISTRIBUTION-V2.pdf (accessed February 13, 2023). 34. Owcharenko Schaefer, “Medicaid at 55: Understanding the Design, Trends, and Reforms Needed to Improve the Health Care Safety Net.” 35. 42 U.S. Code § 1315, https://www.law.cornell.edu/uscode/text/42/1315 (accessed March 17, 2023). 36. Chad D. Savage and Lee S. Gross, “Direct Primary Care: Update and Road Map for Patient-Centered Reforms,” Heritage Foundation Backgrounder No. 3635, June 28, 2021, https://www.heritage.org/sites/default/ files/2021-06/BG3635.pdf. 37. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No. 116-260, 116th Congress, December 27, 2020, Division BB, Title I, https://www.congress.gov/116/plaws/publ260/PLAW-116publ260.pdf (accessed March 17, 2023). 38. Doug Badger, “On Surprise Medical Bills, Congress Should Side with Consumers, Not Special Interests,” Heritage Foundation Commentary, January 31, 2020, https://www.heritage.org/health-care-reform/ commentary/surprise-medical-bills-congress-should-side-consumers-not-special. 39. Edmund F. Haislmaier and Abigail Slagle, “Premiums, Choices, Deductibles, Care Access, and Government Dependence Under the Affordable Care Act: 2021 State-by-State Review,” Heritage Foundation Backgrounder No. 3668, November 2, 2021, https://www.heritage.org/sites/default/files/2021-11/BG3668.pdf. 40. U.S. Department of the Treasury, Internal Revenue Service; U.S. Department of Labor, Employee Benefits Security Administration; and U.S. Department of Health and Human Services, “Transparency in Coverage,” Final Rule, Federal Register, Vol. 85, No. 219 (November 12, 2020), pp. 72158–72310, https://www.govinfo.gov/ content/pkg/FR-2020-11-12/pdf/2020-24591.pdf (accessed March 17, 2023). 41. David N. Bernstein and Robert E. Moffit, “New Price Transparency Rule Will Help Transform America’s Health Care System,” Heritage Foundation Commentary, November 1, 2020, https://www.heritage.org/health-care- reform/commentary/new-price-transparency-rule-will-help-transform-americas-health-care. 42. Sluzala and Haislmaier, “Lessons from COVID-19: How Policymakers Should Reform the Regulation of Clinical Testing.” 43. Ibid. 44. Most recently enacted in H.R. 2471, Consolidated Appropriations Act, 2022, Public Law No. 117-103, 117th Congress, March 15, 2022, Division H, Title V, §§ 506–507, https://www.congress.gov/117/plaws/publ103/ PLAW-117publ103.pdf (accessed March 17, 2023). 45. President Joseph R. Biden Jr., Executive Order 14079, “Securing Access to Reproductive and Other Healthcare Services,” August 3, 2022, in Federal Register, Vol. 87, No. 154 (August 11, 2022), pp. 49505–49507, https:// www.govinfo.gov/content/pkg/FR-2022-08-11/pdf/2022-17420.pdf (accessed March 16, 2023). 46. Planned Parenthood, 2020–2021 Annual Report, p. 27, https://www.plannedparenthood.org/uploads/ filer_public/40/8f/408fc2ad-c8c2-48da-ad87-be5cc257d370/211214-ppfa-annualreport-20-21-c3-digital.pdf (accessed March 22, 2023). 47. Ibid., pp. 30 and 31. Total revenue of $1,714.4 million (p. 30) minus $1,580.7 million in total expenses (p. 31) yields $133,7 million. 48. Ibid., p. 28. 49. Ibid., p. 30. 50. H.R. 372, Protecting Life and Taxpayers Act of 2023, 118th Congress, introduced January 17, 2023, https://www. congress.gov/118/bills/hr372/BILLS-118hr372ih.pdf (accessed March 17, 2023). 51. 42 U.S. Code § 18023, https://www.law.cornell.edu/uscode/text/42/18023 (accessed March 17, 2023). 52. H.R. 3128, Consolidated Omnibus Budget Reconciliation Act of 1985, Public Law No. 99-272, 99th Congress, April 7, 1986, Title IX, Subtitle A, Part 1, Subpart B, § 9121, https://www.congress.gov/99/statute/STATUTE-100/ STATUTE-100-Pg82.pdf (accessed March 17, 2023). 53. H.R. 8070, Rehabilitation Act of 1973, Public Law No. 93-112, 93rd Congress, September 26, 1973, https://www. congress.gov/93/statute/STATUTE-87/STATUTE-87-Pg355.pdf (accessed March 17, 2023). — 501 — Department of Health and Human Services 54. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, Office of Civil Rights, and Office of the Secretary, “Special Responsibilities of Medicare Hospitals in Emergency Cases and Discrimination on the Basis of Disability in Critical Health and Human Service Programs or Activities,” draft of Proposed Rule, January 14, 2021, https://www.hhs.gov/sites/default/files/infants-nprm.pdf (accessed March 17, 2023). 55. H.R. 26, Born-Alive Abortion Survivors Protection Act, 118th Congress, introduced January 9, 2023, https:// www.congress.gov/118/bills/hr26/BILLS-118hr26pcs.pdf (accessed March 17, 2023). 56. H.R. 7, No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2023, 118th Congress, introduced January 9, 2023, https://www.congress.gov/118/bills/hr7/BILLS-118hr7ih.pdf (accessed March 17, 2023). 57. S. 401, Conscience Protection Act of 2021, 117th Congress, introduced February 24, 2021, https://www.congress. gov/117/bills/s401/BILLS-117s401is.pdf (accessed March 17, 2023). 58. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, and Office of the Secretary, “Nondiscrimination in Health Programs and Activities,” Notice of Proposed Rulemaking; Notice of Tribal Consultation, Federal Register, Vol. 87, No. 149 (August 4, 2022), pp. 47824–47920, https://www.govinfo. gov/content/pkg/FR-2022-08-04/pdf/2022-16217.pdf (accessed March 17, 2023). 59. Ibid., p. 47916. 60. The regulation was not finalized before the end of the Administration. U.S. Department of Agriculture, Food and Nutrition Services, “Revision of Categorical Eligibility in the Supplemental Nutrition Assistance Program (SNAP),” Proposed Rule, Federal Register, Vol. 84, No. 142 (July 24, 2019), pp. 35570–55581, https:// www.federalregister.gov/documents/2019/07/24/2019-15670/revision-of-categorical-eligibility-in-the- supplemental-nutrition-assistance-program-snap (accessed March 17, 2023). 61. 45 Code of Federal Regulations § 75.300(c) and (d), https://www.ecfr.gov/current/title-45/subtitle-A/ subchapter-A/part-75/subpart-D/subject-group-ECFR911e5e1a30bfbcb/section-75.300 (accessed March 17, 2023). 62. H.R. 1750, Child Welfare Provider Inclusion Act of 2021, 117th Congress, introduced March 10, 2021, https:// www.congress.gov/117/bills/hr1750/BILLS-117hr1750ih.pdf (accessed March 17, 2023), and S. 656, Child Welfare Provider Inclusion Act of 2021, 117th Congress, introduced March 10, 2021, https://www.congress.gov/117/bills/ s656/BILLS-117s656is.pdf (accessed March 17, 2023). 63. S. 3949, Trafficking Victims Protection Reauthorization Act of 2022, Public Law No. 117-348, 117th Congress, January 25, 2023, https://www.congress.gov/117/plaws/publ348/PLAW-117publ348.pdf (accessed March 17, 2023). 64. Kelsey Y. Santamaria, “Child Migrants at the Border: The Flores Settlement Agreement and Other Legal Developments,” Congressional Research Service In Focus No. IF11799, April 1, 2021, https://crsreports.congress. gov/product/pdf/IF/IF11799 (accessed March 17, 2023). 65. Report, Building a Happy Home: Marriage Education as a Tool to Strengthen Families, Social Capital Project Report No. 1-22, March 2022, p. 17, https://www.jec.senate.gov/public/_cache/files/3d102525-6f0d-48ed- 92f4-d71edd468ad6/building-a-happy-home.pdf (accessed March 17, 2023). The cover of the report reflects that the Social Capital Project is “[a] project of the Joint Economic Committee – Republicans.” 66. See, for example, Alan J. Hawkins, “Are Federally Supported Relationship Education Programs for Lower-Income Individuals and Couples Working? A Review of Evaluation Research,” American Enterprise Institute, September 2019, https://www. congress.gov/117/plaws/publ228/PLAW-117publ228.pdf (accessed March 17, 2023). 67. H.R. 8404, Respect for Marriage Act, Public Law No. 117-228, 117th Congress, December 13, 2022, https://www. congress.gov/117/plaws/publ228/PLAW-117publ228.pdf (accessed March 17, 2023). 68. Madison Marino, “Over 1,000 Safety Violations Mar Head Start. Children Deserve Better,” Heritage Foundation Commentary, November 10, 2022, https://www.heritage.org/education/commentary/over-1000-safety- violations-mar-head-start-children-deserve-better. 69. American Hospital Association v. Becerra, 596 U.S. ___ (2022), https://www.supremecourt.gov/ opinions/21pdf/20-1114_09m1.pdf (accessed March 17, 2023). 70. U.S. Department of the Treasury, Internal Revenue Service; U.S. Department of Labor, Employee Benefits Security Administration; and U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, “Coverage of Certain Preventive Services Under the Affordable Care Act,” Notice of Proposed Rulemaking, Federal Register, Vol. 88, No. 22 (February 2, 2023), pp. 7236–7281, https://www. govinfo.gov/content/pkg/FR-2023-02-02/pdf/2023-01981.pdf (accessed March 17, 2023).

Department of Health and Human Services

Minimal

Vector: 59%

Pages: 488-490AI Enhanced

AI Analysis:

"HR 5160 focuses on reauthorizing stem cell research and cord blood inventory management, with no mention of abortion, fetal tissue research, fertility awareness methods, or data reporting requirements related to pregnancy outcomes. The Project 2025 policy excerpt centers on opposing abortion-related research and promoting specific family planning and data collection agendas, which are entirely absent from the bill's scope."

— 455 — Department of Health and Human Services family formation. It should ensure that it is not promoting abortion as health care. It should fund studies into the risks and complications of abortion and ensure that it corrects and does not promote misinformation regarding the comparative health and psychological benefits of childbirth versus the health and psychological risks of intentionally taking a human life through abortion. The CDC oversaw and funded the development and testing of the COVID-19 vaccines with aborted fetal cell lines, insensitive to the consciences of tens of thousands to hundreds of thousands of people who objected to taking a vac- cine with such a link to abortion. As evidenced by litigation across the country, it is likely that thousands were fired unjustly because of the exercise of their consciences or faith on this question, which could have been avoided with a modicum of concern for this issue from CDC. There is never any justification for ending a child’s life as part of research, and the research benefits from splicing or growing aborted fetal cells and aborted baby body parts can easily be provided by alternative sources. All such research should be prohibited as a matter of law and policy. CDC should update its public messaging about the unsurpassed effectiveness of modern fertility awareness–based methods (FABMs) of family planning and stop publishing communications that conflate such methods with the long-eclipsed “rhythm” or “calendar” methods. CDC should fund studies exploring the evi- dence-based methods used in cutting-edge fertility awareness. Data Collection. The CDC’s abortion surveillance and maternity mortality reporting systems are woefully inadequate. CDC abortion data are reported by states on a voluntary basis, and California, Maryland, and New Hampshire do not submit abortion data at all. Accurate and reliable statistical data about abortion, abortion survivors, and abortion-related maternal deaths are essential to timely, reliable public health and policy analysis. Because liberal states have now become sanctuaries for abortion tourism, HHS should use every available tool, including the cutting of funds, to ensure that every state reports exactly how many abortions take place within its borders, at what gestational age of the child, for what reason, the mother’s state of residence, and by what method. It should also ensure that statistics are separated by category: spontaneous miscarriage; treatments that incidentally result in the death of a child (such as chemotherapy); stillbirths; and induced abortion. In addition, CDC should require monitoring and reporting for complications due to abortion and every instance of children being born alive after an abortion. Moreover, abortion should be clearly defined as only those procedures that intentionally end an unborn child’s life. Miscarriage management or standard ectopic pregnancy treatments should never be conflated with abortion. Comparisons between live births and abortion should be tracked across vari- ous demographic indicators to assess whether certain populations are targeted by — 456 — Mandate for Leadership: The Conservative Promise abortion providers and whether better prenatal physical, mental, and social care improves infant outcomes and decreases abortion rates, especially among those who are most vulnerable. The Ensuring Accurate and Complete Abortion Data Reporting Act of 20239 would amend title XIX of the Social Security Act and Public Health Service Act to improve the CDC’s abortion reporting mechanisms by requiring states, as a condition of federal Medicaid payments for family planning services, to report streamlined variables in a timely manner. The CDC should immediately end its collection of data on gender identity, which legitimizes the unscientific notion that men can become women (and vice versa) and encourages the phenomenon of ever-multiplying subjective identities. FOOD AND DRUG ADMINISTRATION (FDA) The FDA’s mission includes ensuring the safety and efficacy of drugs, biological products, and medical devices. Federal Laws That Shield Big Pharma from Competition. Because generics generally cost far less than brand-name drugs, consumers begin to save money as soon as a generic product comes on the market. The vast majority are very afford- able with 93 percent of generic products costing $20 or less. Savings would be even higher under proposals that prevent brand-name man- ufacturers from slowing down or impeding the entrance of generic products into the marketplace. Specifically, the FDA should prohibit pharmaceutical companies from purposely sitting on their legally available right to be the first to sell generic versions of their drugs. Additionally, Congress should create legal remedies for generic companies to obtain samples of brand-name products for their generic development efforts and should prohibit meritless “citizen petitions” submitted by manufacturers to delay approval of a generic competitor.10 Approval Process for Laboratory-Developed or Modified Medical Tests. Learning from the failed early COVID-19 testing experience, Congress and the FDA should focus on reforming laws and regulations governing medical tests, especially with respect to laboratory-developed tests. Commercial tests are developed with the intention of being widely marketed, distributed, and used, while laboratory-developed tests are created with the intention of being used solely within one laboratory. A test developed by a lab in accordance with the protocols developed by another lab (non-commercial sharing) currently constitutes a “new” laboratory-developed test because the lab in which it will be used is different from the initial developing lab. To encourage interlab- oratory collaboration and discourage duplicative test creation (and associated regulatory and logistical burdens), the FDA should introduce mechanisms through which laboratory-developed tests can easily be shared with other laboratories with- out the current regulatory burdens.11

Department of Health and Human Services

Minimal

Vector: 59%

Pages: 527-529AI Enhanced

AI Analysis:

"HR 5160 focuses on reauthorizing stem cell research and cord blood inventory funding, with no provisions related to religious freedom exemptions, vaccine conscience, Section 1557, or OCR enforcement policies outlined in the Project 2025 excerpt."

Key themes:no overlapunrelated

— 495 — Department of Health and Human Services l HHS should restore OCR authority to review requests for and render opinions on the application of RFRA to requests for religious accommodation of people, families, and doctors who cannot in good conscience take or administer vaccines, including those made or tested with aborted fetal cell lines. l HHS should restore Section 1557, Section 504, and other OCR regulations and fix guidance documents. In 2020, the Trump Administration’s OCR published regulations under Section 1557 of the Affordable Care Act that restored the agency’s enforcement of that law to the limits of its statutory text, deferred to the ACA’s widespread use of a binary biological conception of sex discrimination, and specified that the regulation must comply with the religious exemption and abortion neutrality clauses in Title IX from which it is derived as well as the Religious Freedom Restoration Act and other laws. Courts blocked core provisions of that rule from going into effect. In 2022, the Biden Administration proposed to reinstate a rule contradicting the scope of the statute and imposing nondiscrimination on the basis of sexual orientation and gender identity. It is expected that this rule will be finalized in 2023 even though several courts have issued rulings against the interpretation on which it is based. l OCR should return its enforcement of sex discrimination to the statutory framework of Section 1557 and Title IX. Specifically, it should: 1. Remove all guidance issued under the Biden Administration concerning sexual orientation and gender identity under Section 1557, particularly the May 2021 announcement of enforcement82 and March 2022 statement threatening states that protect minors from genital mutilation.83 2. Issue a general statement of policy specifying that it will not enforce any prohibition on sexual orientation and gender identity discrimination in the Section 1557 regulation and that it will prioritize compliance with the First Amendment, RFRA, and federal conscience laws in any case implicating those claims. DOJ should commit to defending these actions aggressively against inevitable court challenges, including under cases such as Heckler v. Chaney.84 — 496 — Mandate for Leadership: The Conservative Promise 3. Issue a proposed rule to restore the Trump regulations under Section 1557, explicitly interpreting the law not to include sexual orientation and gender identity discrimination based on the textual approach to male and female biology taken by Congress in the ACA, the need to recognize biological distinctions as part of the sound practice of health care, and the need to ensure protections of medical judgment and conscience. DOJ should agree to defend this rule to the Supreme Court if necessary. 4. Issue a general statement of policy announcing that it plans to enforce Section 1557 discrimination bans by refocusing on serious cases of race, sex, and disability discrimination. In particular, OCR should highlight its 2019 investigation and voluntary resolution agreement with Michigan State University based on the sexual abuse of gymnasts by Larry Nassar. OCR should also coordinate with the Department of Education on a public education and civil rights enforcement campaign to ensure that female college athletes who become pregnant are no longer pressured to obtain abortions; pursue race discrimination claims against entities that adopt or impose racially discriminatory policies such as those based on critical race theory; and announce its intention to enforce disability rights laws to protect children born prematurely, children with disabilities, and children born alive after abortions. 5. Issue and finalize the Trump-era draft disability rights regulations concerning crisis standards of care and use of Quality of Life Adjusted Years (QALYs), and reissue and finalize a disability regulation (withdrawn by the Biden Administration) that prohibited discriminatory application of assisted suicide and denial of life-saving treatments for disabled newborns. l OCR should withdraw its pharmacy abortion mandate guidance. OCR should withdraw its “Obligations Under Federal Civil Rights Laws to Ensure Access to Comprehensive Reproductive Health Care Services” guidance for retail pharmacies,85 which purports to address nondiscrimination obligations of pharmacies under federal civil rights laws and in fact orders them to stock and dispense first-trimester abortion drugs. The guidance invents this so-called requirement and fails to acknowledge that pharmacies and pharmacists have the right not to participate in abortions, including pill-induced abortions, if doing so would violate their sincere moral or religious objections. Moreover, no federal civil rights laws preempt state pro-life statutes.

Showing 3 of 5 policy matches

About These Correlations

Policy matches are calculated using a hybrid approach: initial candidates are found using semantic similarity between bill summaries and Project 2025 policy text, then an AI model (Llama 3.1 70B) provides detailed alignment ratings and analysis. Ratings range from 1 (minimal alignment) to 5 (very strong alignment). This analysis does not imply direct causation or intent.

Related Bills

Other Bills by Rep. Smith, Christopher H.

To reauthorize the Kay Hagan Tick Act, and for other purposes.

119/hr/4348

United States Commission on International Religious Freedom Reauthorization Act of 2026

119/hr/1744

Frederick Douglass Trafficking Victims Prevention and Protection Reauthorization Act of 2025

119/hr/1144

Back to All Bills